Achieving Access to High Quality Care Across the Spectrum of Age and Patient Type to Improve Overall Outcomes for Atopic Dermatitis

Module 1: Management of Atopic Dermatitis in Pediatric Patients
Module 2: Management of Atopic Dermatitis in Adult Patients

• Release Date: July 31, 2024
• Expiration Date: January 31, 2026
• Estimated Time to Complete Activity: 0.5 hour per module
• Compatible with all modern browsers and mobile devices

Expert Faculty

Joy Wan, MD, MSCE Assistant Professor of Dermatology John Hopkins University School of Medicine Click here for biography Heather Woolery-Lloyd, MD, FAAD Director, Skin of Color Division Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Click here for biography

Target Audience
This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
Managed care professionals are not on the forefront of dermatologic care for those pediatric and adult patients living with atopic dermatitis. In this program, learners will explore the challenges patients living with atopic dermatitis face and they will identify opportunities to collaborate and address elements of access and outcomes in AD.

Educational Objectives
After completing this activity, the participant should be better able to:

Module 1:

1. Explain the challenges that pediatric patients with moderate-to-severe AD and their caregivers experience and the recommended treatment options
2. Assess opportunities to collaborate and apply fair drug coverage policies to atopic dermatitis treatments
3. Identify opportunities to address elements that contribute to the disparities in access and outcomes in atopic dermatitis

Module 2:

1. Explain the challenges that adult patients with moderate-to-severe AD experience and the recommended treatment options
2. Assess opportunities to collaborate and apply fair drug coverage policies to atopic dermatitis treatments
3. Identify opportunities to address elements that contribute to the disparities in access and outcomes in atopic dermatitis

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
PACE designates these enduring activities for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 1: 0.5 AMA PRA Category 1 Credit™
Module 2: 0.5 AMA PRA Category 1 Credit™

Continuing Pharmacy Education
PACE designates these continuing education activities for 0.5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.

Module 1: JA4008073-9999-24-178-H01-P - 0.5 contact hour. This activity is certified as Application-based CPE.
Module 2: JA4008073-9999-24-179-H01-P - 0.5 contact hour. This activity is certified as Application-based CPE.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Continuing Nursing Education
The maximum number of hours awarded for these Continuing Nursing Education activities is 0.5 contact hour.

Module 1: Management of Atopic Dermatitis in Pediatric Patients – 0.5 contact hour
Module 2: Management of Atopic Dermatitis in Adult Patients – 0.5 contact hour

Disclosures of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.